
Mortgage Debt: Hidden U.S. Estate Tax Trap For Foreign Investors
Foreign investors are often very surprised to learn that a leveraged U.S. real estate investment ... More using recourse debt will often not shield the foreign investor from U.S. estate tax exposure. This article explores the mortgage debt surprise, why it matters, and how foreign investors can navigate it. getty
Foreign investment in U.S. real estate is quite significant with investors being drawn because of the market's stability, robust and reliable legal protections, and the potential for capital growth. U.S. real estate is a core wealth-building strategy for nonresident alien individuals (those who are not U.S. citizens and are not domiciled in the U.S.).
Many NRA investors are caught off-guard by various aspects of the U.S. estate tax which is imposed at death on the fair market value of U.S. situs assets, such as American real estate. The maximum estate tax rate of 40% can certainly take a big chunk out of the investment. With experienced U.S. tax advice, foreigners can carefully plan their investment strategies to minimize (if not eliminate) this tax.
A lesser-known aspect of the U.S. estate tax regime involves the limited deductibility of recourse mortgage debt on U.S. real property. A leveraged real estate investment using recourse debt will often not shield the foreign investor from U.S. estate tax exposure. This article explores the mortgage debt surprise, why it matters, and how foreign investors can navigate it.
When an NRA passes away owning U.S. real estate, which is a U.S.-situs asset, the value of that property is included in their U.S. taxable estate, subject to estate tax rates up to 40%. Many investors assume they can deduct the full amount of any mortgage tied to the property from its fair market value thus reducing the taxable estate. This would make sense since the net equity represents the NRA's economic interest in the property. The U.S. tax rules, however, apply a different rule for recourse versus nonrecourse debt often creating a costly surprise to the estate.
By way of overview, when a mortgage debt is 'recourse', it allows the lender to pursue other assets of the borrower (or his estate) if there is any shortfall if the property's sale will not cover the amount loaned. Thus, in the case of a decedent, the estate is held liable for the debt. Nonrecourse mortgage debt limits the lender's recovery to the property itself; the creditor has 'no recourse' to the estate's other assets.
Under the U.S. estate tax rules, nonrecourse debt is fully deductible to offset the value of the U.S. real property. The lender can seize only the real property and no other assets and the estate isn't liable for any shortfall. Permitting the full mortgage loan to offset the value of the property reflects the estate's true economic interest, as the lender has no claim on other assets.
In the case of recourse debt, however, only a portion of recourse mortgage debt is deductible by the estate. The deductible amount is proportional to the ratio of the U.S.-situs assets' value to the value of the decedent's worldwide assets.
Here is an example. Assume an NRA has a worldwide estate valued at $10 million. This includes $2 million of U.S. real property which is encumbered by a $1 million recourse mortgage. The U.S. property represents 20% of the worldwide estate ($2M/$10M), so only 20% of the mortgage ($200,000) can be deducted. The taxable value in the estate of $1.8 million can result in an approximate estate tax of $720,000 (assuming no exemptions or credits). The distinction between recourse and nonrecourse debt catches out many investors who are relying on leverage to maximize returns and are expecting the full debt to offset their U.S. estate tax exposure. In this example, the result will come as a surprise since the investor's expectation would be that the U.S. property would have a $1 million taxable value after deducting the full mortgage. Why The U.S. Estate Tax Limitation for Recourse Debt?
The limitation on deducting recourse mortgage debt for U.S. estate tax purposes is a mechanism to prevent the estate being able to offset U.S. estate tax using a global debt obligation even when the estate has other non-U.S. assets to repay the loan. Recourse debt renders the estate liable for repayment, potentially using worldwide assets. The tax law restricts the mortgage deduction in such a case to prevent an over-reduction of the U.S. taxable estate.
The deduction is made proportional to the U.S.-situs assets' share of the worldwide estate precisely because the estate's liability for the debt is not limited to U.S. assets. This ensures the U.S. taxes the estate's net U.S. property value while accounting for global obligations, unlike nonrecourse debt, which is fully deductible because it is tied only to the equity in the U.S. property. The pro-rata formula is found in IRC Section 2106(a)(1) and its relevant Treasury Regulations and Treasury Regulation Section 20.2053-7.
Assume an NRA owns U.S. real estate having a value of $5 million and that it is subject to a $3 million recourse mortgage. The NRA has foreign assets worth $15 million. Without the recourse debt limitation, the $3M recourse debt would be fully deductible, and the NRA's U.S. taxable estate would be just $2M. This would permit the estate to offset U.S. estate tax using a global debt obligation, even though the estate has $15M of foreign assets with which to repay the loan. To prevent overly reducing the U.S. taxable estate, the pro-rate formula is used. U.S. Real Property - The Surprise Recourse Debt Limitation Really Matters
The limited deduction for recourse debt can dramatically increase tax liabilities, particularly given the low $60,000 estate tax exemption for NRAs (compared to $13.99 million for U.S. citizens and domiciliaries in 2025). Even modest U.S. real estate holdings can trigger significant taxes.
In addition, calculating the proportional deduction requires disclosing the fair market value of the decedent's worldwide assets on IRS Form 706-NA. Such disclosure raises serious privacy concerns for investors who do not wish to reveal their global holdings. This disclosure requirement, combined with the unexpected tax burden, makes the recourse mortgage debt rule a double blow for unprepared investors. Strategies Can Mitigate The Mortgage Debt Problem
There are various strategies foreign investors can adopt, depending on the facts and the investor's priorities. A qualified tax professional can assist, balancing favorable tax outcomes with practical considerations. For example, ownership structures can avoid U.S. estate tax but involve more complexity, costs and tax compliance; the investor can opt for nonrecourse debt which will mean the full debt amount can reduce the taxable estate but likely means higher interest rates or stricter terms will apply, since the lender bears greater risk. Life insurance can be explored, as well as the possible use of estate tax treaties.
Every strategy will involve trade-offs, making professional advice indispensable. Proactive planning can help the U.S. real estate investment remain lucrative without the harsh surprise of unexpected estate tax liability.
Stay on top of tax matters around the globe.
Reach me at vljeker@us-taxes.org
Visit my US tax blog www.us-tax.org
NO ATTORNEY-CLIENT RELATIONSHIP OR LEGAL ADVICE
This communication is for general informational purposes only. It is not intended to constitute tax advice or a recommended course of action. Professional tax advice should be sought as the information here is not intended to be, and should not be, relied upon by the reader in making a decision.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
15 minutes ago
- Associated Press
Lake Street Capital Partners Establishes New Residential Services Platform HighPoint Exterior Home Services by Partnering with Choufani & Bailey Roofing & Restoration
CHICAGO, June 30, 2025 /PRNewswire/ -- Lake Street Capital Partners, LP ('Lake Street Capital Partners' or 'Lake Street Cap'), a Chicago-based private equity firm, is pleased to announce the establishment of Exterior Home Services, LLC, doing business as HighPoint Exterior Home Services ('HighPoint'), a new investment platform focused on roofing and related exterior residential services. In combination with this launch, Lake Street Capital Partners has also completed its majority investment in Choufani & Bailey Roofing & Restoration, LLC ('Choufani & Bailey' or the 'Company'). Choufani & Bailey is a North Carolina based provider of exterior home repair, replacement, and remodeling services. Founded in Wilmington, North Carolina, Choufani & Bailey has established itself as a trusted partner to homeowners, property managers, and HOA organizations in need of critical roofing, gutter, siding, and window repair or replacement. The Company's primary focus is to provide retail services to these customers while also bringing the industry expertise to service any, and all, insurance related work for its customer base. More recently, Choufani & Bailey successfully demonstrated the transferability of its model with the recent expansion to the Raleigh market, bringing its differentiated go-to-market strategy and core focus of delivering exceptional customer service and quality to this strategic growth market. 'We are extremely excited to be partnering with the Lake Street Capital Partners team to support and accelerate the growth plans we are executing on at Choufani & Bailey,' said James Bailey, Co-Founder of Choufani & Bailey. 'James and I were committed to finding a proven growth partner to continue to bring our Company's unique value proposition to more customers across the East Coast, " added Sharbel Choufani, Co-Founder of Choufani & Bailey. 'The opportunity to create a partnership with Justin, Brant, and the rest of the Lake Street Capital team to achieve this goal was a no-brainer.' 'Choufani & Bailey represents the perfect company to launch our new platform, HighPoint Exterior Home Services,' said Brant Wilczek, Managing Director of Lake Street Capital Partners. 'James, Sharbel, and the rest of the Choufani & Bailey team have created tremendous brand equity within their core market. Providing them with the resources and strategic support to continue expanding their presence to other highly attractive markets represented a compelling opportunity for us at Lake Street Cap.' 'This latest transaction demonstrates the continued momentum we are experiencing across the residential services sector at Lake Street Cap,' added Justin Terzo, Managing Partner of Lake Street Capital Partners. 'Home services continue to remain attractive due to its recession resilient nature, untapped organic growth potential within many of the sector's operating companies, and opportunity for strategic regional and national market expansion.' As part of the transaction, Lake Street Capital Partners was represented by Stinson LLP and Miller Cooper & Co., Ltd. Choufani & Bailey was advised by Amdel Associates, Inc. About HighPoint Exterior Home Services HighPoint Exterior Home Services was created in 2025 as a platform focused on local and regional companies providing exceptional roofing and related exterior services to homeowners and property managers. The platform was launched in concert with the investment in Choufani & Bailey, an expert in residential roofing replacement and renovation projects serving the Raleigh and Wilmington, North Carolina markets. For more information on HighPoint Exterior Home Services and Choufani & Bailey, please visit About Lake Street Capital Partners, LP Lake Street Capital Partners, LP ('Lake Street Cap') is a Chicago-based private equity firm focused on making control, significant minority, and co-investments in North American based lower middle market companies across the consumer, services, and distribution sectors. Lake Street Cap seeks to invest in growth-oriented founders and family-owned businesses in search of a strategic and value-added capital partner. Lake Street Cap typically makes equity investments of $5 million to $15 million per transaction. For more information, please visit or contact [email protected]. View original content to download multimedia: SOURCE Lake Street Capital Partners


Associated Press
29 minutes ago
- Associated Press
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
– The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension – –Lorundrostat 50 mg once daily demonstrated clinically meaningful reductions in systolic blood pressure, with a 16.9 mmHg reduction at Week 6 and a 19.0 mmHg reduction at Week 12– –Lorundrostat was generally well-tolerated; and treatment-emergent adverse events were mostly mild, transient, and resolved without intervention – RADNOR, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced the publication of the positive results from the pivotal Phase 3 Launch-HTN trial in the Journal of the American Medical Association (JAMA). The manuscript titled 'Lorundrostat in Participants with Uncontrolled and Treatment-Resistant Hypertension' is featured in the June 30, 2025 issue. The Launch-HTN trial evaluated the efficacy and safety of lorundrostat, a novel aldosterone synthase inhibitor (ASI), when added to existing background treatment in 1,083 participants with uncontrolled or treatment resistant hypertension. The trial demonstrated that lorundrostat significantly reduced systolic blood pressure (BP) with a favorable safety and tolerability profile. 'Hypertension remains the most prevalent and preventable driver of cardiovascular disease globally, yet a significant proportion of patients continue to struggle with inadequate blood pressure control. We believe lorundrostat has the potential to be a best-in-class treatment for patients with uncontrolled or treatment resistant hypertension,' said Jon Congleton, Chief Executive Officer of Mineralys Therapeutics. 'We are pleased to have the results of Launch-HTN published in a medical journal as prestigious as JAMA. The consistency of results seen in the lorundrostat development program – which includes multiple trials across differentiated patient populations – supports its potential to have a broad role in future hypertension care.' 'Launch-HTN was the largest Phase 3 trial of an ASI in patients with uncontrolled or resistant hypertension, designed to reflect usual clinical practice. It demonstrated consistent blood pressure lowering efficacy and safety with the aldosterone synthase inhibitor, lorundrostat, across a diverse group of patients,' said Dr. Manish Saxena, MBBS, Deputy Clinical Co-Director of Queen Mary University of London's William Harvey Heart Centre, and Hypertension Specialist at Barts Health NHS Trust and lead investigator on the study. 'Dysregulated aldosterone, a key factor in driving hypertension in up to 30% of all hypertensive patients, is a consistent feature of treatment-resistant hypertension and related cardiovascular morbidities, such as heart failure and chronic kidney disease, making aldosterone synthase inhibition an attractive treatment target. Lorundrostat, a novel ASI therapy, is a promising development that could help address unmet clinical needs for patients who remain hypertensive despite multiple medications.' Key Findings from Launch-HTN The Launch-HTN trial was a global, randomized, double-blinded, placebo-controlled Phase 3 trial, which enrolled 1,083 eligible adult participants who failed to achieve their BP goal despite being on two to five antihypertensive medications. Launch-HTN reflects the real-world setting for clinicians by utilizing automated office blood pressure (AOBP) measurements and allowing participants to stay on their existing medications. Authors noted that the trial recruited a diverse population as reflected in the high proportion of females, Black or African American and elderly participants. When added to existing background treatment, lorundrostat 50 mg dosed once daily demonstrated clinically meaningful, statistically significant mean reductions in AOBP with a 16.9 mmHg reduction at Week 6 (-9.1 mmHg placebo adjusted; p-value < 0.0001) that was sustained with a reduction of 19.0 mmHg at Week 12 (-11.7 mmHg placebo adjusted; p-value < 0.0001). These benefits were consistent across age, sex, race, body mass index, and baseline medication regimen. Lorundrostat demonstrated a favorable safety and tolerability profile in the Launch-HTN trial. The anticipated on-target effects on serum electrolytes, increased serum potassium and reduced serum sodium were modest and rapidly reversible upon discontinuation of lorundrostat. A confirmed serum potassium level of greater than 6.0 mmol/L occurred in three subjects (0.6%) on lorundrostat 50 mg once daily, as compared to one subject (0.4%) on placebo. Suppression of cortisol production was not observed, and there was a very low incidence of drug-related serious adverse events resulting in discontinuation or dose-adjustment of study medication. About Hypertension Having sustained, elevated BP (or hypertension) increases the risk of heart disease, heart attack and stroke, which are leading causes of death in the United States.1 In 2022, more than 685,000 deaths in the United States included hypertension as a primary or contributing cause.2 Hypertension and related health issues resulted in an estimated annual economic burden of about $219 billion in the United States in 2019.3 Less than 50% of hypertension patients achieve their BP goal with currently available medications.4 Dysregulated aldosterone levels are a key factor in driving hypertension in approximately 30% of all hypertensive patients.5 About Lorundrostat Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as CKD and OSA. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in hypertensive subjects. About Mineralys Therapeutics Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD, and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit Follow Mineralys on LinkedIn, Twitter and Bluesky. Forward Looking Statements Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the potential therapeutic benefits of lorundrostat; the Company's expectation that ASIs with an SGLT2 inhibitor may provide additive clinical benefits to patients; the Company's expectation that Advance-HTN and Launch-HTN may serve as pivotal trials in submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA); the Company's ability to evaluate lorundrostat as a potential treatment for CKD, OSA, uHTN or rHTN; the planned future clinical development of lorundrostat and the timing thereof; and the expected timing of commencement and enrollment of participants in clinical trials and topline results from clinical trials. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: topline results that we report are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial; our future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; later developments with the FDA may be inconsistent with the feedback from the completed end of Phase 2 meeting, including whether the proposed pivotal program will support registration of lorundrostat which is a review issue with the FDA upon submission of an NDA; the results of our clinical trials, including the Advance-HTN and Launch-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for an NDA submission or regulatory approval of lorundrostat; our dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs, and the potential for a local and/or global economic recession; our ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; our reliance on our exclusive license with Mitsubishi Tanabe Pharma to provide us with intellectual property rights to develop and commercialize lorundrostat; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading 'Risk Factors' in our annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. References 1 CDC. Facts About Hypertension. Centers for Disease Control and Prevention. Updated September 27, 2023. Accessed June 2025. 2 CDC. Underlying Cause of Death, 1999–2022 Results. CDC WONDER Online Database. Accessed June 2025. 3 Centers for Disease Control and Prevention. Health and Economic Benefits of High Blood Pressure Interventions. National Center for Chronic Disease Prevention and Health Promotion. Updated November 20, 2023. Accessed June 2025. 4 Carey RM, et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement from the AHA. Hypertension. 2018;72(5):e53-e90. 5 Brown JM, et al. Primary Aldosteronism and the Pathogenesis of Hypertension. Physiol Rev. 2018;98(1):103-137. Contact: Investor Relations [email protected] Media Relations Melyssa Weible Elixir Health Public Relations Phone:1-201-723-5805 Email: [email protected]

Yahoo
41 minutes ago
- Yahoo
Bond yields and U.S. dollar to continue moving lower: JPM
-- Bond yields and the U.S. dollar are likely to continue their downward trajectory as markets increasingly price in interest rate cuts by the Federal Reserve, according to JPMorgan analysts. In their latest equity strategy note, the bank said investor attention has shifted toward the timing and implications of expected monetary easing in the second half of 2025. 'Judging from the incoming queries, investors are refocusing on the timing and the likely impact of the potential Fed cuts in 2H,' JPMorgan wrote. The bank explains that the Fed futures market now reflects more than 64 basis points of cuts, roughly two full rate reductions, by year-end, with September and December as the likely windows. The note added, 'The pricing in of cuts has accelerated in the past couple of weeks, during which an extra 18bp of easing was added.' JPMorgan sees the most constructive scenario for markets as one where the Fed cuts rates amid 'resilient growth [and] subdued inflation,' calling it a 'Goldilocks' environment. In this case, they added, 'USD might be unexciting.' However, the bank's base case is a mix of two less favorable outcomes: economic slowdown coupled with inflation pressure driven by tariffs. In such a scenario, 'bond yields are likely to keep moving lower,' and 'our call is to stay bearish USD.' JPMorgan believes this setup should favor emerging market equities, reiterating its overweight stance. It also noted that sectors such as Utilities, Staples, Healthcare, and IT tend to outperform during easing cycles, while Financials typically lag. The firm continues to advise caution in Europe, maintaining a more defensive regional allocation strategy. Related articles Bond yields and U.S. dollar to continue moving lower: JPM Should you buy or sell the U.S. dollar over a three-to-six month period? Asia FX slides as Israel attacks Iran, dollar jumps on safe-haven demand Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data